12th Bio-Pune Seminar Series

12th Bio-Pune Seminar Series: Symposium on Cancer Immunotherapy: Immune Checkpoint Inhibitors

Kindly note that this is a Tentative Outline and is subject to change

Potential gains
  • Get an overview of current status of immunotherapies in India and abroad, key issues / emerging opportunities
  • Understand drug development and regulatory processes for immunotherapy drug approvals
  • Understand diagnostic space/requirements in this domain
  • Network and explore potential industry-academia-clinical partnerships
  • Get expert opinions on key areas with potential for entrepreneurship
  • Obtain CME Credits
  • Learn about possible funding opportunities in this domain
Organized and Supported by
  • Venture Center
  • Prashanti Cancer Care Mission
  • Bioincubator at Venture Center (Bioincubator at Venture Center is supported by BIRAC, Government of India)
  • Sponsor/Partner Options: BMS, Core Diagnostics, Roche,
For whom
  • Innovators and technologists
  • Clinicians (medical oncologists, pathologists)
  • Researchers
  • Pharma/Biotech Industry professionals
  • Entrepreneurs/ startups with interest in cancer diagnostics and immunotherapy
When Saturday, June 24th 2017 Time: 8:30am – 6:30pm
Where Lecture Theatre, Venture Center, 900 NCL Innovation Park, Dr. Homi Bhabha Road, Pune-411008
Contact Ms. Lipika Biswas, Venture Center
Phone: +91-20-25865875/76/77 | Email: eventsdesk@venturecenter.co.in
Registration Process/ Cost

Step 1: Interested participants need to fill in registration form at the following link.
Step 2: Email invite will be sent post screening of registration details.
Step 3: Attendance only on confirmation of payment of Rs. 1000/-

Note:

  • First preference to clinicians, innovators and technologists, industry professionals, entrepreneurs, senior researchers with keen interest in setting up collaborations
  • Students shall be allowed to participate if seats are available.
  • Organizers reserve the right to select participants so as to maximize learning and networking opportunities for the group.
  • Maximum number of allowed attendees: 80

Introduction

Immunotherapy includes the use of antibodies, cancer vaccines or engineered immune cells that aid the immune system in specifically eliminating cancer cells. Clinical trials for a class of cancer immunotherapies known as Immune Checkpoint Inhibitors have shown significantly increased survival rates in patient with several types of malignant cancers. While selected ICIs have been approved for use in the US and EU, they have recently begun entering the Indian market.

The event will focus on Immune Checkpoint Inhibitors in the Indian Scenario and aim at understanding the following:

Event Outline

Event shall consist of:

Event includes

*Please note, the participants will have to arrange for their own travel/local transport and accommodation and meals.

Tentative Event Schedule
Time Session title Faculty
8:30-9:00am Registration : 900 Foyer Area  
9:00-9:30am Welcome and Introduction to the theme of the session:
- About VC
- About PCCM
Dr. Premnath (Director, VC)
Dr. Koppiker (Director, PCCM)
9:30-10:15am Keynote Lecture: Overview of Cancer Immunotherapy, Immune Checkpoints and
Path forward
Dr. Raju Titus Chacko
(CMC, Vellore)
10:15-10:45am Session 1: Checkpoint Inhibition in Cancer - Basic Biology and Milestones in Discovery To be decided
10:45-11:15am Session 2: Immune Checkpoint Therapy - Journey from Bench to Bedside Dr. Raman Govindarajan
(Sanofi, Bangalore)
11:15-11:30am Tea Break  
  Clinical Applications of Checkpoint Inhibitors  
11:30-12:00pm Session 4: Clinical applications of checkpoint inhibitors – anti-PD-1 Therapeutics Dr. Kumar Prabash
(TMH, Mumbai)
12:00-12:30pm Session 5: Clinical applications of checkpoint inhibitors – anti-PDL-1 Therapeutics Dr. Chetan Deshmukh
(PCCM)
12:30-1:30pm Session 6: Panel Discussion Chair : by Dr. Sudeep Gupta,
Dy.Director ACTREC, Navi Mumbai
1:30-2:15pm Lunch Break  
  Diagnostics in Immune Checkpoint Therapy  
2:15-2:45pm Session 7: Pathology Considerations To be decided
2:45-3:15pm Session 8: Role of diagnostics in effective ICI Therapy Dr. Shalu Verma
(Core Diagnostics, Gurgaon)
3:15-4:15pm Session 9: Genomics Based Approaches for ICI Therapy Dr. Aarti Desai
(Affymetrix/ThermoFisher, Bangalore)
4:15-4:45pm Session 10: Liquid Biopsy Applications in ICI management To be decided
4:45pm –5:00pm 15 min break  
  Regulatory Processes and Market Considerations  
5:00-5:30pm Session 11: Regulatory Approval for ICI Therapeutics Dr. Bangarurajan
(CDSCO, Mumbai) or TBD?
5:30-6:00pm Session 12: ICI Therapy: Market Realities To be decided
6:00-6:30pm Session 13: Investing in ICI: Potential areas for Innovation Entrepreneurship Dr. Ajit Singh
(Artiman Ventures, Palo Alto, CA,
USA)
6:30pm onwards Mixer & Networking Dinner (By Invitation Only)  

About the Organizers

Entrepreneurship Development Center (Venture Center) – a CSIR initiative – is a Section 25 company hosted by the National Chemical Laboratory, Pune. Venture Center strives to nucleate and nurture technology and knowledge-based enterprises by leveraging the scientific and engineering competencies of the institutions in the Pune region in India. The Venture Center is a technology business incubator supported by the Department of Science & Technology's National Science & Technology Entrepreneurship Development Board (DST-NSTEDB). Venture Center's focuses on technology enterprises offering products and services exploiting scientific expertise in the areas of materials, chemicals and biological sciences & engineering.
For more information, visit: http://www.venturecenter.co.in

 

Prashanti Cancer Care Mission (PCCM) is a registered, public charitable trust in Pune. The trust works with the goal of providing affordable medical treatment to cancer patients and undertaking medical education, training and research. PCCM has established Orchids Breast Health Center (OBHC)-a Center of Affordable Excellence for Breast Care- well-equipped with advanced cancer diagnostics, chemotherapy day-care unit along-with expert Oncologists and allied healthcare professionals. PCCM has been conferred with a Scientific and Industrial Research Organization (SIRO) status by the Department of Scientific and Industrial Research (DSIR) , Government of India. PCCM has also a member of the National Cancer Grid Research Consortium of India co-ordinated by Tata Memorial Center, Mumbai.
For more information, visit: http://www.prashanticancercare.org

About us


Coping With Cancer

 




Copyright © 2015 Prashanti Cancer Care Mission. All rights reserved.
Made by webvings